SCHEMBL1254191

SCHEMBL1254191

NP(O)O.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@]2(O)F)c(=O)n1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3A Q14432 3/20 0.73
PDE4D Q08499 1/20 0.73
SLC29A1 Q99808 1/20 0.73
LMNA P02545 5/20 0.55
MTOR P42345 2/20 0.55
THRB P10828 1/20 0.55
MDM2 Q00987 1/20 0.55
NCOA1 Q15788 1/20 0.55
NCOA3 Q9Y6Q9 1/20 0.55
POLA1 P09884 2/20 0.47
CACNA1F O60840 2/20 0.45
ALB P02768 2/20 0.45
MAPT P10636 2/20 0.45
CACNA1D Q01668 2/20 0.45
CACNA1S Q13698 2/20 0.45
CACNA1C Q13936 2/20 0.45
NT5E P21589 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15316783 0.95 PDE3A (0.80) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL232223 0.95 PDE3A (0.80) PDE3APDE4DSLC29A1LMNAMTOR
Phosphoric Acid SCHEMBL4576320 0.91 PDE3A (0.73) PDE3APDE4DSLC29A1LMNAMTOR
Phosphoric Acid SCHEMBL20769295 0.91 PDE3A (0.73) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL1254196 0.87 PDE3A (0.58) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL17184312 0.86 PDE3A (0.67) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL29574822 0.85 PDE3A (0.71) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL32672458 0.85 PDE3A (0.62) PDE3APDE4DSLC29A1LMNAMTOR
Gemcitabine SCHEMBL12503065 0.85 PDE3A (1.00) PDE3APDE4DSLC29A1LMNAMTOR
Gemcitabine SCHEMBL6761683 0.85 PDE3A (1.00) PDE3APDE4DSLC29A1LMNAMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879991-B2 CGRP binding nucleic acids NOXXON PHARMA AG (DE) 2011-02-01 US disclosed
US-7629447-B2 Dideoxynucleoside derivatives WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2009-12-08 US disclosed
US-20080064868-A1 Novel Dideoxynucleoside Derivatives WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2008-03-13 US disclosed
US-20060183700-A1 Cgrp binding nucleic acids NOXXON PHARMA AG (DE) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064868-A1 Novel Dideoxynucleoside Derivatives DNA2, DDX20, DNASE1 PDE3A 3110/4885PDE4D 3408/4885SLC29A1 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.